Crescentis Capital is a non-banking financial company that provides loans to small businesses, healthcare providers, and renewable energy projects while managing a portfolio of stock market investments.
The company lacks a durable competitive advantage as its primary income has historically been volatile investment gains rather than unique lending capabilities. While it is pivoting to niche lending in healthcare and MSME sectors, the low average ROCE of 6.4% and negative cash conversion indicate no significant pricing power or cost advantage.
Management has shifted focus from proprietary equity trading to building a lending book, funded largely by a significant rights issue in 2025. While they have successfully raised capital, the historical returns on that capital have been poor, and the current strategy involves lending to related parties which raises conflict of interest concerns.
The company's pivot from volatile proprietary trading to niche lending collapsed under the weight of its own poor capital allocation. By funneling capital raised from shareholders into related-party entities rather than building a genuine credit culture, the firm suffered massive impairments when those insider loans soured. The negative cash conversion and interest coverage observed years prior were not temporary glitches but symptoms of a business model that consumed cash without generating real returns, eventually leading to a liquidity crisis that wiped out equity value.
RichFakir rates Crescentis Capital Ltd's business quality as poor — 27/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Crescentis Capital Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Crescentis Capital Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Crescentis Capital Ltd's fair value is about ₹7 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →